Peringatan Keamanan

The most common adverse events (?10%) are dyspnea, diarrhea, nausea, cough, and arteriovenous fistula site complication.

Peginesatide

DB08894

biotech approved investigational

Deskripsi

Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and ?-alanine. FDA approved March 27, 2012.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) IV dose, healthy subjects = 25.0 ± 7.6 hours; SubQ, healthy subjects = 53.0 ± 17.7 hours; IV dose, dialysis patients = 47.9 ± 16.5 hours;
Volume Distribusi IV dose, dialysis patients = 34.9 ± 13.8 mL/kg;
Klirens (Clearance) Systemic clearance, IV dose, dialysis patients = 0.5 ± 0.2 mL/hr•kg

Absorpsi

Tmax, SubQ dose = 48 hours; Bioavailability, SubQ dose = 46%; Peginesatide does not accumulate when administered every 4 weeks following intravenous or subcutaneous administration.

Metabolisme

Preclinical radiolabeled peginesatide study indicated that peginesatide is not metabolized.

Rute Eliminasi

Peginesatide administered intravenously or subcutaneously is primarily excreted via urine. Most of the excreted dose is in the form of unchanged drug. Elimination from the plasma is biphasic and rapid from vascular compartments. In contrast, the drug is selectively retained in sites of erythropoiesis like the bone marrow.

Interaksi Obat

1296 Data
Pegfilgrastim The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegfilgrastim.
Peginterferon alfa-2b The therapeutic efficacy of Peginesatide can be decreased when used in combination with Peginterferon alfa-2b.
Pegademase The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegademase.
Pegvisomant The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegvisomant.
Propylene glycol The therapeutic efficacy of Peginesatide can be decreased when used in combination with Propylene glycol.
Heptaethylene glycol The therapeutic efficacy of Peginesatide can be decreased when used in combination with Heptaethylene glycol.
Egaptivon pegol The therapeutic efficacy of Peginesatide can be decreased when used in combination with Egaptivon pegol.
PEG-uricase The therapeutic efficacy of Peginesatide can be decreased when used in combination with PEG-uricase.
Peginterferon alfacon-1 The therapeutic efficacy of Peginesatide can be decreased when used in combination with Peginterferon alfacon-1.
GlycoPEG-GCSF The therapeutic efficacy of Peginesatide can be decreased when used in combination with GlycoPEG-GCSF.
Pegnivacogin The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegnivacogin.
Pegpleranib The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegpleranib.
Pegsunercept The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegsunercept.
Polidocanol The therapeutic efficacy of Peginesatide can be decreased when used in combination with Polidocanol.
Methoxy polyethylene glycol-epoetin beta The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginesatide.
Peginterferon beta-1a The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Peginesatide.
Pegloticase The therapeutic efficacy of Pegloticase can be decreased when used in combination with Peginesatide.
Polyethylene glycol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginesatide.
Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Peginesatide.
Eptacog alfa pegol (activated) The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Peginesatide.
Olaptesed Pegol The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Peginesatide.
Abicipar Pegol The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Peginesatide.
Lexaptepid pegol The therapeutic efficacy of Lexaptepid pegol can be decreased when used in combination with Peginesatide.
Cepeginterferon alfa-2B The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Peginesatide.
Pegvaliase The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Peginesatide.
Pegamotecan The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Peginesatide.
Lipegfilgrastim The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Peginesatide.
Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Peginesatide.
Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Peginesatide.
Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginesatide.
Nandrolone phenpropionate The therapeutic efficacy of Peginesatide can be increased when used in combination with Nandrolone phenpropionate.
Nandrolone decanoate The therapeutic efficacy of Peginesatide can be increased when used in combination with Nandrolone decanoate.
Nandrolone The therapeutic efficacy of Peginesatide can be increased when used in combination with Nandrolone.
Cyclosporine Cyclosporine may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Icosapent Icosapent may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefotiam Cefotiam may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Mesalazine Mesalazine may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefmenoxime Cefmenoxime may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefmetazole Cefmetazole may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Indomethacin Indomethacin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cidofovir Cidofovir may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefpiramide Cefpiramide may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Ceftazidime Ceftazidime may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Loracarbef Loracarbef may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefalotin Cefalotin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Nabumetone Nabumetone may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Ketorolac Ketorolac may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Tenoxicam Tenoxicam may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Celecoxib Celecoxib may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefotaxime Cefotaxime may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Tolmetin Tolmetin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Foscarnet Foscarnet may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Rofecoxib Rofecoxib may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Piroxicam Piroxicam may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cephalexin Cephalexin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Fenoprofen Fenoprofen may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Valaciclovir Valaciclovir may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Valdecoxib Valdecoxib may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Diclofenac Diclofenac may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Sulindac Sulindac may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Bacitracin Bacitracin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Amphotericin B Amphotericin B may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cephaloglycin Cephaloglycin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Flurbiprofen Flurbiprofen may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Pentamidine Pentamidine may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Etodolac Etodolac may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Mefenamic acid Mefenamic acid may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Acyclovir Acyclovir may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Naproxen Naproxen may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Sulfasalazine Sulfasalazine may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Phenylbutazone Phenylbutazone may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Meloxicam Meloxicam may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Carprofen Carprofen may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefaclor Cefaclor may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Diflunisal Diflunisal may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Tacrolimus Tacrolimus may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Ceforanide Ceforanide may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Salicylic acid Salicylic acid may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Oxaprozin Oxaprozin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Ketoprofen Ketoprofen may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Balsalazide Balsalazide may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Ibuprofen Ibuprofen may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefditoren Cefditoren may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Atazanavir Atazanavir may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Colistimethate Colistimethate may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefuroxime Cefuroxime may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefapirin Cefapirin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefadroxil Cefadroxil may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefprozil Cefprozil may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Ceftriaxone Ceftriaxone may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Olsalazine Olsalazine may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Lumiracoxib Lumiracoxib may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefamandole Cefamandole may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefazolin Cefazolin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefonicid Cefonicid may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Cefoperazone Cefoperazone may decrease the excretion rate of Peginesatide which could result in a higher serum level.

Target Protein

Erythropoietin receptor EPOR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 23506424
    Schmid H: Peginesatide for the treatment of renal disease-induced anemia. Expert Opin Pharmacother. 2013 May;14(7):937-48. doi: 10.1517/14656566.2013.780695. Epub 2013 Mar 18.
  • PMID: 22188389
    Woodburn KW, Holmes CP, Wilson SD, Fong KL, Press RJ, Moriya Y, Tagawa Y: Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica. 2012 Jul;42(7):660-70. doi: 10.3109/00498254.2011.649310. Epub 2011 Dec 22.
  • PMID: 23318685
    Woodburn KW, Fong KL, Wilson SD, Sloneker S, Strzemienski P, Solon E, Moriya Y, Tagawa Y: Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. Drug Metab Dispos. 2013 Apr;41(4):774-84. doi: 10.1124/dmd.112.048033. Epub 2013 Jan 14.

Contoh Produk & Brand

Produk: 8 • International brands: 0
Produk
  • Omontys
    Solution • 1 mg/0.5mL • Intravenous; Parenteral; Subcutaneous • US • Approved
  • Omontys
    Solution • 2 mg/0.5mL • Intravenous; Parenteral; Subcutaneous • US • Approved
  • Omontys
    Solution • 3 mg/0.5mL • Intravenous; Parenteral; Subcutaneous • US • Approved
  • Omontys
    Solution • 4 mg/0.5mL • Intravenous; Parenteral; Subcutaneous • US • Approved
  • Omontys
    Solution • 5 mg/0.5mL • Intravenous; Parenteral; Subcutaneous • US • Approved
  • Omontys
    Solution • 6 mg/0.5mL • Intravenous; Parenteral; Subcutaneous • US • Approved
  • Omontys
    Solution • 10 mg/1mL • Intravenous; Parenteral; Subcutaneous • US • Approved
  • Omontys
    Solution • 20 mg/2mL • Intravenous; Parenteral; Subcutaneous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul